<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555828</url>
  </required_header>
  <id_info>
    <org_study_id>EMT-AB001</org_study_id>
    <nct_id>NCT00555828</nct_id>
  </id_info>
  <brief_title>Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction</brief_title>
  <official_title>A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angioblast Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angioblast Systems</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective The primary objective of this study is to evaluate the safety and&#xD;
      feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping&#xD;
      Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of 25 M, 75 M, and&#xD;
      150 M allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI.&#xD;
&#xD;
      SecondaryObjective&#xD;
&#xD;
      The secondary objectives are to explore functional efficacy for subsequent study design, as&#xD;
      well as late-term dose related tolerance, by:&#xD;
&#xD;
        -  Evaluating the effect of allogeneic MPCs on exploratory efficacy endpoints related to&#xD;
           cardiac function on Days 90, 180, and 1 year&#xD;
&#xD;
        -  Evaluating the change from baseline in the Medical Outcome Study Short Form (SF-36),&#xD;
           Kansas City Cardiomyopathy Questionnaire, Seattle Angina Questionnaire, and the New York&#xD;
           Heart Association Classification at 30 days, 3 and 6 months, and 1, 2, and 3 years&#xD;
&#xD;
        -  Evaluating follow-up safety through Day 360&#xD;
&#xD;
        -  Providing preliminary data to support dose selection for future studies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore efficacy for subsequent study design and dose related tolerance: •Effect related to cardiac function.•Change from baseline in SF-36, KCCQ, SAQ, and the NYHA Classification.•Follow-up safety through Day 360 • Dose selection for future stu</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>25 M allogeneic MPCs by transendocardial injection</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard-of-care treatment with NOGA® mapping and staged injections.</intervention_name>
    <description>Standard-of-care treatment with NOGA® mapping and staged injections.</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>75 M allogeneic MPCs by transendocardial injection</description>
    <arm_group_label>B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard-of-care treatment with NOGA® mapping and staged injections.</intervention_name>
    <description>Standard-of-care treatment with NOGA® mapping and staged injections.</description>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>150 M allogeneic MPCs by transendocardial injection</description>
    <arm_group_label>C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard-of-care treatment with NOGA® mapping and staged injections.</intervention_name>
    <description>Standard-of-care treatment with NOGA® mapping and staged injections.</description>
    <arm_group_label>C2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. An ST-elevation MI (STEMI) within 2 to 10 days of study enrollment. The STEMI must be&#xD;
             documented by ECG with ST-segment elevation &gt;1 mm in at least 2 contiguous precordial&#xD;
             leads or in at least 2 adjacent limb leads. If there is a history of a previous AMI&#xD;
             prior to the qualifying MI, then there must be a documented EF ≥ 50% by 2D&#xD;
             echocardiogram within 12 months of enrollment.&#xD;
&#xD;
          3. Successful percutaneous revascularization with Thrombolysis in Myocardial Infarction&#xD;
             (TIMI)-3 flow of the infarct-related artery.&#xD;
&#xD;
          4. A baseline 2D echocardiogram with EF ≥ 30 and ≤ 50% following PCI.&#xD;
&#xD;
          5. Creatinine level ≤ 1.5mg/dL within 24 hours of study procedure.&#xD;
&#xD;
          6. Hematocrit ≥ 30% within 24 hours of study procedure.&#xD;
&#xD;
          7. White Blood Cell count &lt; 20k/mm3 within 24 hours of study procedure.&#xD;
&#xD;
          8. Platelet count ≥ 100k/mm3 within 24 hours of study procedure.&#xD;
&#xD;
          9. INR ≤ 1.7 within 24 hours of study procedure.&#xD;
&#xD;
         10. Total bilirubin &lt;3 mg/dL, albumin &gt;2.8 g/dL, aspartate aminotransferase(AST) ≤ 2.5x&#xD;
             the upper limit of normal, gamma glutamyltranspeptidase (GGT) ≤ 1.5 x the upper limit&#xD;
             of normal.&#xD;
&#xD;
         11. If the subject or partner is of childbearing potential, he or she must be willing to&#xD;
             use adequate contraception (hormonal or barrier method or abstinence) from the time of&#xD;
             screening and for a period of at least 16 weeks after surgery.&#xD;
&#xD;
         12. Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening (within 2 weeks of enrollment) and a negative serum or urine pregnancy test&#xD;
             on the day of cell implantation.&#xD;
&#xD;
         13. Willing and able to understand, sign, and date the Informed Consent Form (ICF).&#xD;
&#xD;
         14. Must be willing to return for required follow-up visits.&#xD;
&#xD;
         15. Must be able to follow postoperative management program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is hemodynamically unstable at Day 5 post-AMI as demonstrated by any of the&#xD;
             following:&#xD;
&#xD;
               1. Killip Class 4 indicative of cardiogenic shock.&#xD;
&#xD;
               2. Requirement of intra-aortic balloon pump or IV inotropic support for the&#xD;
                  maintenance of mean arterial blood pressure ≥ 60 mmHg.&#xD;
&#xD;
          2. Sustained ventricular tachycardia as demonstrated by QRS complexes wider than 120&#xD;
             msec, lasting &gt;30 secs, and &gt;100 bpm occurring &gt;48 hours following PCI without any&#xD;
             identifiable, reversible cause (ie, electrolyte imbalance).&#xD;
&#xD;
          3. Further revascularization planned for the next 30 days.&#xD;
&#xD;
          4. Chronic atrial fibrillation.&#xD;
&#xD;
          5. A wall thickness in the target region &lt;8 mm as determined by 2D echocardiography(the&#xD;
             target region is defined at the time of NOGA® mapping).&#xD;
&#xD;
          6. An LV thrombus.&#xD;
&#xD;
          7. Severe peripheral vascular disease precluding femoral artery access as determined at&#xD;
             time of original catheterization.&#xD;
&#xD;
          8. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter&#xD;
             access to the LV.&#xD;
&#xD;
          9. Echocardiographic evidence of hypertrophic cardiomyopathy indicating heart muscle&#xD;
             thickness &gt;15 mm.&#xD;
&#xD;
         10. Human immunodeficiency virus (HIV)&#xD;
&#xD;
         11. Serum glucose level ≥ 400 mg/dl within 24 hours of study procedure&#xD;
&#xD;
         12. Serum glucose level 300-400 mg/dl and presence of urine ketones within 24 hours of&#xD;
             study procedure.&#xD;
&#xD;
         13. Claustrophobic, or with medical conditions or contradictions that impede performing&#xD;
             baseline MRI study.&#xD;
&#xD;
         14. An active uncontrolled infection.&#xD;
&#xD;
         15. A prosthetic aortic valve.&#xD;
&#xD;
         16. Presence of ≥ 20% anti-HLA antibody titers and/or having antibody specificities to&#xD;
             donor HLA antigens.&#xD;
&#xD;
         17. A current or prior history within the last 3 years of neoplasm (excluding basal cell)&#xD;
             and/or any active neoplasm within the last 24 months.&#xD;
&#xD;
         18. A known hypersensitivity to dimethyl sulfoxide (DMSO), murine and/or bovine products.&#xD;
&#xD;
         19. Pregnancy or breastfeeding.&#xD;
&#xD;
         20. Imprisoned at the time of enrollment.&#xD;
&#xD;
         21. A treatment and/or an uncompleted follow-up treatment of any investigational therapy&#xD;
             within 6 months before implantation surgery and intent to participate in any other&#xD;
             investigational drug or cell therapy study during the 3-year follow-up period of this&#xD;
             study.&#xD;
&#xD;
         22. Active participation in other research therapy for cardiovascular repair/regeneration.&#xD;
&#xD;
         23. A prior recipient of stem precursor cell therapy for cardiac repair.&#xD;
&#xD;
         24. Any medical condition that would affect the investigator's ability to evaluate the&#xD;
             subject's condition or could compromise the subject's safety.&#xD;
&#xD;
         25. Any condition that, in the judgment of the investigator, would prohibit the subject&#xD;
             from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emerson C. Perin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Heart Institute/St. Luke's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Skerrett, MD</last_name>
    <phone>1-888-369-2123</phone>
    <email>donna.skerrett@angioblast.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota/Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407-1139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy D. Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute/St. Luke's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emerson C. Perin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Donna Skerrett, MD ; Medical Director</name_title>
    <organization>Angioblast Systems</organization>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial infarct</keyword>
  <keyword>Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

